ET-21 COMBINATION OF INTRAVENOUS AND INTRACEREBRAL INJECTION OF ONCOLYTIC PARVOVIRUS H-1 IN A PHASE I/IIA CLINICAL TRIAL OF PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: PENETRATION OF H-1 VIRUS ACROSS THE BLOOD-BRAIN BARRIER

Lignende værker

• Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol
  af: Geletneky, Karsten, et al.
  Udgivet: (2012)
• ATNT-07 FAVORABLE RESPONSE OF PATIENTS WITH GLIOBLASTOMA AT SECOND OR THIRD RECURRENCE TO REPEATED INJECTION OF ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB
  af: Geletneky, Karsten, et al.
  Udgivet: (2015)
• Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
  af: Geletneky, Karsten, et al.
  Udgivet: (2017)
• Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
  af: Angelova, Assia L., et al.
  Udgivet: (2017)
• Bioavailability, Biodistribution, and CNS Toxicity of Clinical-Grade Parvovirus H1 after Intravenous and Intracerebral Injection in Rats
  af: Geletneky, Karsten, et al.
  Udgivet: (2015)